169 related articles for article (PubMed ID: 22285669)
1. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669
[TBL] [Abstract][Full Text] [Related]
2. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
3. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
Am J Clin Oncol; 2018 Jan; 41(1):59-64. PubMed ID: 26325492
[TBL] [Abstract][Full Text] [Related]
10. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.
Woo SM; Kim MK; Joo J; Yoon KA; Park B; Park SJ; Han SS; Lee JH; Hong EK; Kim YH; Moon H; Kong SY; Kim TH; Lee WJ
Cancer Res Treat; 2017 Oct; 49(4):1022-1032. PubMed ID: 28111423
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Nakachi K; Furuse J; Kinoshita T; Kawashima M; Ishii H; Ikeda M; Mitsunaga S; Shimizu S
Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB
Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305
[TBL] [Abstract][Full Text] [Related]
13. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.
Krishnan S; Chadha AS; Suh Y; Chen HC; Rao A; Das P; Minsky BD; Mahmood U; Delclos ME; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):755-65. PubMed ID: 26972648
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer.
Goto Y; Nakamura A; Ashida R; Sakanaka K; Itasaka S; Shibuya K; Matsumoto S; Kanai M; Isoda H; Masui T; Kodama Y; Takaori K; Hiraoka M; Mizowaki T
Radiat Oncol; 2018 Jun; 13(1):118. PubMed ID: 29940984
[TBL] [Abstract][Full Text] [Related]
15. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.
Nakamura A; Shibuya K; Matsuo Y; Nakamura M; Shiinoki T; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):369-75. PubMed ID: 22381898
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Goji T; Kimura T; Miyamoto H; Takehara M; Kagemoto K; Okada Y; Okazaki J; Takaoka Y; Miyamoto Y; Mitsui Y; Matsumoto S; Sueuchi T; Tanaka K; Fujino Y; Takaoka T; Kitamura S; Okamoto K; Kimura M; Sogabe M; Muguruma N; Okahisa T; Sato Y; Sagawa T; Fujikawa K; Sato Y; Ikushima H; Takayama T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):615-20. PubMed ID: 26220846
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
Nakamura A; Itasaka S; Takaori K; Kawaguchi Y; Shibuya K; Yoshimura M; Matsuo Y; Mizowaki T; Uemoto S; Hiraoka M
Strahlenther Onkol; 2014 May; 190(5):485-90. PubMed ID: 24599344
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Uchikado Y; Arigami T; Uenosono Y; Mori S; Ueno S; Shinchi H; Natsugoe S
Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
[TBL] [Abstract][Full Text] [Related]
19. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
[TBL] [Abstract][Full Text] [Related]
20. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
